Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats

Hypertension

Volumn 25, Issue 2, 1995, Pages 250-259

  Bruckschlegel, Günter ^a   Holmer, Stephan R ^a   Jandeleit, Karin ^b   Grimm, Daniela ^a   Muders, Frank ^a   Kromer, Eckhard P ^a   Riegger, Günter A J ^a   Schunkert, Heribert ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

angiotensin converting enzyme inhibitors; hypertrophy, left ventricular; ramipril; receptors, angiotensin; renin angiotensin system

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ATRIAL NATRIURETIC FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; LOSARTAN; MESSENGER RNA; RAMIPRIL; RENIN;

ANIMAL MODEL; ANIMAL TISSUE; AORTA CLAMPING; ARTICLE; CONTROLLED STUDY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE SIZE; HEART STRESS; MALE; NEUROENDOCRINOLOGY; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SARCOPLASMIC RETICULUM;

EID: 0028837105     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.25.2.250     Document Type: Article

References (44)

1. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;56:56-64.
2. Katz AM. Cardiomyopathy of overload: a major determinant of prognosis in congestive heart failure. N Engl J Med. 1990; 322:100-110.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WB. Prognostic implications of echocardiographically determined LV mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
4. Schulman SP, Weiss JL, Becker LC, Gottlieb SO, Woodruff KM, Weisfeldt ML, Gerstenblith G. The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med. 1990;322:1350-1356.
5. Cruickshank JM. Reversibility of left ventricular hypertrophy (LVH) by differing types of antihypertensive therapy. J Hum Hypertens. 1992;6:85-90.
6. Kromer EP, Riegger GAJ. Effects of long-term angiotensin converting enzyme inhibition on myocardial hypertrophy in experimental aortic stenosis in the rat. Am J Cardiol. 1988;62:161-163.
7. Kromer EP, Elsner D, Riegger GAJ. Role of neurohumoral systems for pressure induced left ventricular hypertrophy in experimental supravalvular aortic stenosis in rats. Am J Hypertens. 1991;4:521-524.
8. von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH. Renin is not synthesized by cardiac and extrarenal vascular tissues: a review of experimental evidence. Circulation. 1994;89:458-470.
9. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine: a paradigm shift? Circulation. 1994;89:493-498.
10. Schunkert H, Hense H-W, Holmer SR, Stender K, Perz S, Keil U, Lorell BH, Riegger GAJ. Association between a deletion polymorphism of the angiotensin-converting enzyme gene and left ventricular hypertrophy. N Engl J Med. 1994;330:1634-1638.
11. 1 receptor subtype. Circ Res. 1993;73:413-423.
12. Geenen DL, Malhorta A, Scheuer J. Angiotensin II increases cardiac protein synthesis in adult rat heart. Am J Physiol. 1993; 265(suppl 1):H238-H243.
13. Linz W, Schölkens BA, Ganten D. Converting enzyme inhibition prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens A. 1989;11:1325-1350.
14. Schunkert H, Jackson B, Tang SS, Schoen FJ, Smits JFM, Apstein CS, Lorell BH. Distribution and functional significance of cardiac ACE in hypertrophied rat hearts. Circulation. 1993;87:1328-1339.
15. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiotensin-converting enzyme activity and mRNA levels in pressure overload left ventricular hypertrophy: effects on coronary resistance, contractility and relaxation. J Clin Invest. 1990;86:1913-1920.
16. Schunkert H, Ingelfinger JR, Hirsch AT, Tang SS, Litwin SE, Talsness CE, Dzau VJ. Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest. 1992;90:1523-1529.
17. Devereux RB, Reicheck N. Echocardiographic determination of left ventricular mass in man. Circulation. 1977;55:613-618.
18. Anversa P, Palackal T, Sonnenblick EH, Olivetti G, Meggs LG, Capasso JM. Myocyte cell loss and myocyte cellular hyperplasia in the hypertrophied aging rat heart. Circ Res. 1990;67:871-875.
19. Kinoshita A, Urata H, Bumpus FM, Husain A. Measurement of angiotensin I converting enzyme inhibition in the heart. Circ Res. 1993;73:51-60.
20. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979;18:5294-5299.
21. Schunkert H, Ingelfinger JR, Hirsch AT, Pinto Y, Remme WJ, Jacob H, Dzau VJ. Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. Circ Res. 1993;72:312-318.
22. Takahashi T, Schunkert H, Isoyama S, Wei JY, Nadal-Ginard B, Grossman W, Izumo S. Age-related differences in the expression of proto-oncogene and contractile protein genes in response to pressure overload in the rat myocardium. J Clin Invest. 1992;89:939-946.
23. 2+-ATPase. FEBS Lett. 1989;249:35-41.
24. Fort P, Marty L, Piechaczyk M, Sabrouty SE, Dany C, Jaenteur P, Blanchard JM. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate dehydrogenase multigenic family. Nucleic Acids Res. 1985;13:1431-1442.
25. Morgan HE, Baker KM. Cardiac hypertrophy: mechanical, neural, and endocrine dependence. Circulation. 1991;83:13-26.
26. Feldman AM, Weinberg EO, Ray PE, Lorell BH. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res. 1993;73:184-192.
27. Kromer EP. Rolle der sympathischen Aktivität bei der experimentellen adaptiven Myokardhypertrophie. In: Riegger G, ed. Hypertonie. Stuttgart, Germany: Schattauer; 1993:23-31.
28. Zierhut W, Zimmer HG, Gerdes AM. Effect of angiotensin converting enzyme inhibition on pressure-induced left ventricular hypertrophy in rats. Circ Res. 1991;69:609-617.
29. Wiemer G, Schölkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 1991;18:558-563.
30. Linz W, Schölkens BA. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol. 1992;105:771-772.
31. Garr MD, McDonald KM, Francis GS, Cohn JN. The influence of an angiotensin II inhibitor (DuP 532) on ventricular remodeling in a canine model of discrete myocardial damage. Clin Res. 1992; 40:702A. Abstract.
32. Qing G, Garcia R. Chronic captopril and losartan (DuP 753) administration in rats with high-output heart failure. Am J Physiol. 1992;263(pt):H833-H840.
33. Linz W, Henning R, Schölkens BA. Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats. J Hypertens. 1991; 9(suppl 6):S400-S401.
34. Baker KM, Chernin MI, Wixson SK, Aceto JF. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol. 1990;259:H324-H332.
35. Mercadier JJ, Samuel JL, Michel JB, Zongazo MA, de la Bastie D, Lompre AM, Wisnewsky C, Rappaport L, Levy B, Schwartz K. Atrial natriuretic factor gene expression in rat ventricle during experimental hypertension. Am J Physiol. 1989;257:H979-H987.
36. Studer R, Reinecke H, Müller B, Holtz J, Drexler H. Increased angiotensin-I converting enzyme gene expression in the failing human heart: quantification by competitive RNA polymerase chain reaction. J Clin Invest. 1994;94:301-310.
37. Suzuki J, Matsubara H, Urakami M, Inada M. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res. 1993;73:439-447.
38. Eberli FR, Apstein CS, Ngoy S, Lorell B. Exacerbation of left ventricular ischemic diastolic dysfunction by pressure-overload hypertrophy: modification by specific inhibition of cardiac angiotensin-converting enzyme. Circ Res. 1992;70:931-943.
39. Haber HL, Powers ER, Gimple LW, Wu CC, Subbiah K, Johnson WH, Feldman MD. Intracoronary angiotensin-converting enzyme inhibition improves diastolic function in patients with hypertensive left ventricular hypertrophy. Circulation. 1994;89:2616-2625.
40. Hirsch AT, Talsness CE, Smith AD, Schunkert H, Ingelfinger JR, Dzau VJ. Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. Circulation. 1992;86:1566-1574.
41. 125I-MK 351A binding studies of plasma and tissue ACE during variation of salt status in the rat. J Hypertens. 1986;4:759-765.
42. Sadoshima J, Xu J, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993;75:977-984.
43. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
44. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.